{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77"}]}],"title":"ADA Positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"51"}]}],"title":"nAb Positive"}],"denoms":[{"counts":[{"groupId":"OG000","value":"433"}],"units":"Participants"}],"groups":[{"description":"Participants with aRCC received avelumab 10 mg/kg, IV at Q2W in a 6-week cycle plus axitinib 5 mg, orally BID. Each treatment cycle was 42 days.","id":"OG000","title":"Avelumab + Axitinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Immunogenicity analysis set included all participants who received at least one dose of study drug and who had at least one ADA/nAb sample collected for avelumab in \"Avelumab + Axitinib\" arm. Here \"Number of Participants Analyzed\" signifies participants evaluable for this outcome measure. This outcome measure was not planned to be analyzed for ''Sunitinib'' reporting group.","reportingStatus":"POSTED","timeFrame":"From start of treatment until 30 days after the end of avelumab treatment (maximum up to approximately 89 months)","title":"Number of Participants With Positive Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (nAb) of Avelumab When Used in Combination With Axitinib","type":"SECONDARY","unitOfMeasure":"Participants"}